Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


U.S.-Japan regulatory reform

This article was originally published in The Gray Sheet

Executive Summary

AdvaMed is working with the Commerce Department to prepare the federal government's September/October submission of issues to be addressed by the Regulatory Reform Initiative. Released June 26, the1 U.S. Trade Representative/Japan's first annual report on the initiative represents "solid first steps in solving the current health care crisis in Japan," according to the association. Absent from the report, which lists such planned reforms as increasing the frequency of reimbursement price redesignations, are U.S. industry's concerns with Japanese foreign reference pricing. A Commerce official noted that the topic of reference pricing was excluded from the final report because the U.S. did not want to lend credence to a policy it opposes...

You may also be interested in...

Premium pricing policy

AdvaMed may work with the Commerce Department to address premium pricing concerns via the second report on the Regulatory Reform Initiative by the U.S. Trade Representative and Japan, expected by October. The first annual report was released June 26 (1"The Gray Sheet" July 1, 2002, In Brief). The effects of the policy, which allows devices to receive a temporary price within 90 days of launch and guarantees a permanent price within six months, should become clearer following several months of implementation and a "working level" AdvaMed trip to Japan in July. The trade group also will help guide the agenda of a health economics conference in Tokyo, currently scheduled for Sept. 19...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts